<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benzalkonium chloride and benzocaine (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benzalkonium chloride and benzocaine (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Benzalkonium chloride and benzocaine (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="87455" href="/d/html/87455.html" rel="external">see "Benzalkonium chloride and benzocaine (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56743459"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Orajel Cold Sore</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F15826924"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Topical Skin Product</li></ul></div>
<div class="block doa drugH1Div" id="F15826955"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a48df1f4-1825-4275-b7f0-78387b0123be">Cold sore/fever blister</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Cold sore/fever blister:</b>
<b>Topical:</b> Apply single dose to cold sore with applicator; may repeat up to 3 times daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991999"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989253"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dop drugH1Div" id="F15826954"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a48df1f4-1825-4275-b7f0-78387b0123be">Cold sore/fever blister</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cold sore/fever blister:</b> Topical: Children &gt;2 years and Adolescents: Refer to adult dosing.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090206"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51090207"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F15826930"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">There are no adverse reactions listed in the manufacturer's labeling. See individual agents.</p></div>
<div class="block coi drugH1Div" id="F15826927"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">
<i>OTC labeling:</i> When used for self-medication, do not use if you have hypersensitivity to benzalkonium chloride, benzocaine, other ester-type local anesthetics, or any component of the formulation; for ophthalmic use or for teething; use over a large area of body or &gt;3 times daily; children &lt;2 years of age; longer than 1 week unless directed by health care provider.</p></div>
<div class="block war drugH1Div" id="F15826928"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication, notify health care provider if condition worsens or does not improve within 7 days.</p></div>
<div class="block foc drugH1Div" id="F56743460"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Liquid, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Orajel Cold Sore: Benzalkonium chloride 0.13% and benzocaine 5% (4s) [contains isopropyl alcohol]</p></div>
<div class="block geq drugH1Div" id="F15826923"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F15826958"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Topical: Prior to administration, clean lotions, ointments, or cosmetics from the lip using only warm water and a washcloth. Saturate the applicator with solution and apply to the cold sore. Allow a few moments for the lip to numb, then massage the solution (using the applicator) into the cold sore by rubbing firmly without damaging the skin. Avoid brushing with toothpaste or drinking fruit juices or soft drinks for at least one hour after application.</p></div>
<div class="block admp drugH1Div" id="F52616762"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: Children ≥2 years and Adolescents: Prior to administration, clean lip area with warm water and washcloth; remove any residual lotions, ointments, or cosmetics. Saturate the applicator with solution and apply to the cold sore. Allow a few moments for the lip to numb, then massage the solution (using the applicator) into the cold sore by rubbing firmly without damaging the skin. Avoid brushing with toothpaste or drinking fruit juices or soft drinks for at least 1 hour after application. A residual fine white powder at the application site may appear at the application site and is normal; it is unabsorbed benzocaine.</p></div>
<div class="block use drugH1Div" id="F15826926"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Cold sore/fever blister</b>: Topical treatment of cold sores or fever blisters</p></div>
<div class="block mst drugH1Div" id="F54873942"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Benzocaine, when used in pediatric patients &lt;2 years of age for teething or pharyngitis, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of methemoglobinemia (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F15896779"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F15896777"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F15826934"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Fruit juices and soft drinks may deactivate the active ingredient. Management: Avoid drinking fruit juices and soft drinks for at least 1 hour after application.</p></div>
<div class="block pha drugH1Div" id="F15826937"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Benzalkonium chloride is an antiseptic and disinfectant; benzocaine is an ester local anesthetic that blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benzalkonium-chloride-and-benzocaine-topical-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Orajel Touch Free Cold Sore (benzalkonium chloride and benzocaine) [prescribing information]. Ewing Township, NJ: Church &amp; Dwight Co Inc; received April 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 87454 Version 72.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
